/
/
/

Brooks Laboratories Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020
₹23 Cr₹20 Cr₹17 Cr₹23 Cr₹26 Cr₹23 Cr₹21 Cr₹21 Cr₹18 Cr₹18 Cr₹22 Cr₹24 Cr₹16 Cr₹13 Cr₹15 Cr₹18 Cr₹17 Cr₹28 Cr₹19 Cr₹21 Cr₹22 Cr₹15 Cr₹21 Cr₹29 Cr
₹18 L₹44 L₹13 L₹39 L₹22 L₹62 L₹3 L₹20 L₹7 L₹65 L₹16 L₹9 L₹6 L₹3 L₹9 L₹14 L₹3 L₹18 L₹37 L₹56 L₹70 L₹6 L₹4 L₹52 L
₹23 Cr₹21 Cr₹17 Cr₹24 Cr₹26 Cr₹24 Cr₹21 Cr₹21 Cr₹18 Cr₹18 Cr₹22 Cr₹24 Cr₹16 Cr₹13 Cr₹15 Cr₹18 Cr₹17 Cr₹29 Cr₹19 Cr₹22 Cr₹22 Cr₹15 Cr₹21 Cr₹30 Cr
₹22 Cr₹20 Cr₹16 Cr₹21 Cr₹23 Cr₹22 Cr₹19 Cr₹20 Cr₹18 Cr₹18 Cr₹21 Cr₹23 Cr₹16 Cr₹13 Cr₹26 Cr₹30 Cr₹28 Cr₹34 Cr₹27 Cr₹27 Cr₹24 Cr₹20 Cr₹23 Cr₹26 Cr
₹2 Cr₹1 Cr₹86 L₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹35 L₹1 Cr₹1 Cr₹2 Cr₹8 L-₹9 L-₹8 Cr-₹9 Cr-₹9 Cr-₹4 Cr-₹6 Cr-₹4 Cr₹33 L-₹4 Cr-₹62 L₹6 Cr
₹21 L₹9 L₹16 L₹28 L₹30 L₹26 L₹28 L₹32 L₹16 L₹27 L₹21 L₹19 L₹17 L₹18 L₹75 L₹63 L₹62 L₹84 L₹74 L₹75 L₹76 L₹74 L₹78 L₹80 L
₹1 Cr₹61 L₹30 L₹2 Cr₹3 Cr₹2 Cr₹94 L₹96 L-₹21 L₹30 L₹60 L₹1 Cr-₹53 L-₹71 L-₹11 Cr-₹12 Cr-₹11 Cr-₹7 Cr-₹9 Cr-₹7 Cr-₹2 Cr-₹6 Cr-₹3 Cr₹3 Cr
₹1 Cr₹61 L₹30 L₹2 Cr₹3 Cr₹1 Cr₹94 L₹96 L-₹21 L₹30 L₹58 L₹1 Cr-₹53 L-₹71 L-₹9 Cr-₹8 Cr-₹9 Cr-₹6 Cr-₹7 Cr-₹5 Cr-₹1 Cr-₹17 Cr-₹3 Cr₹3 Cr

Share Price Live Stats

Open (₹)67.80
Volume (₹)2.15 L
High (₹)71.70
Upper Circuit77.71
Low (₹)65.46
Lower Circuit51.81
Prev Close64.76
52W High (₹)130.98
Price68.72
52W Low (₹)36.30

Share Market Cap & Key Ratios Overview

M.Cap (₹)190.56 Cr
Div. Yield (%)0.00
PE Ratio14.42
Debt to Equity0.06
Price to Book0.90
Book Value41.64
EPS (TTM)4.49
Face Value10.00
ROE (%)22.27

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
LAURUSLABSNSE
CIPLANSE
DRREDDYNSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
BROOKSNSE
LTP
1W Low
1W High
Market cap (₹)
1746.4-13.6 (-0.77%)
1725.50
1776.60
4,24,466Cr
9023-317 (-3.39%)
8937.50
9431.50
2,46,222Cr
4580-76.9 (-1.65%)
4551.80
4682
1,76,301Cr
1124.7+7.2 (0.64%)
1107.30
1150.90
1,12,818Cr
2036.9+0.3 (0.01%)
2007.80
2069.20
1,10,823Cr
1314.6+13.6 (1.05%)
1300.20
1333.30
1,07,447Cr
1216+19 (1.59%)
1196.90
1250.70
1,03,471Cr
2335-33.5 (-1.41%)
2317.50
2426.80
97,850Cr
1662.9-30.1 (-1.78%)
1654.10
1715
96,836Cr
1953.2-3.3 (-0.17%)
1925.70
1964.90
89,629Cr
68.72-1.41 (-2.01%)
63.30
73.45
191Cr

Key Highlights of Brooks Laboratories Ltd’s P&L

In 2026-03-31, Brooks Laboratories Ltd reported total revenue of ₹86.91Cr, compared with ₹87.04Cr in 2025-03-31, reflecting Brooks Laboratories Ltd turnover.

Depreciation was ₹1.59Cr and finance costs were ₹83.53Lakh in 2026-03-31

Profit Before Tax (PBT) has been ₹24.58Cr in 2026-03-31 as compared to ₹-₹9.79Cr in 2025-03-31.

Net Profit (PAT) was ₹24.58Cr in 2026-03-31 compared with ₹-₹9.97Cr in 2025-03-31.

Earnings per share (EPS) were ₹8.35 in 2026-03-31, compared with ₹-3.38 in 2025-03-31.